NFKB1 and metabolic dysfunction-associated steatohepatitis: Namodenoson exerts an anti-nonalcoholic steatohepatitis effect that is mediated by the deregulation of the PI3K/NFκB/Wnt/β-catenin signaling pathway [29, 30].